Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interpretable QSAR, External PubChem Validation, and Coordination-Aware Docking Enable Tiered Prioritization of Carbonic Anhydrase I Inhibitors.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Interpretable QSAR models for acute oral toxicity via tuned XGBoost and hybrid data sampling techniques.

Scientific reports·2026
Same author

Development of novel amino-benzenesulfonamide derivatives and their analogues as carbonic anhydrase inhibitors: Design, synthesis, anticancer activity assessment, and pharmacokinetic studies using UPLC-MS/MS.

Bioorganic chemistry·2025
Same author

Corrigendum to "Sulfonamides as anticancer agents: A brief review on sulfonamide derivatives as inhibitors of various proteins overexpressed in cancer" [Bioorg. Chem. 147 (2024) 107409].

Bioorganic chemistry·2024
Same author

Sulfonamides as anticancer agents: A brief review on sulfonamide derivatives as inhibitors of various proteins overexpressed in cancer.

Bioorganic chemistry·2024
Same author

Classification of Biodegradable Substances Using Balanced Random Trees and Boosted C5.0 Decision Trees.

International journal of environmental research and public health·2020

Related Experiment Video

Updated: May 5, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

300

Interpretable QSAR and Complementary Docking for PARP1 Inhibitor Prioritization: Reliability Stratification and

Alaa M Elsayad1, Khaled A Elsayad2

  • 1Biomedical Group, Department of Electrical Engineering, College of Engineering, Prince Sattam Bin Abdulaziz University, Wadi Alddawasir 11991, Saudi Arabia.

Pharmaceuticals (Basel, Switzerland)
|May 4, 2026
PubMed
Summary

This study developed a cheminformatics workflow to prioritize Poly(ADP-ribose) polymerase 1 (PARP1) inhibitors for cancer therapy. The approach combines quantitative structure-activity relationship (QSAR) modeling with structural analysis to identify promising drug candidates.

Keywords:
PARP1QSARexplainable AIlead prioritizationmolecular dockingnear-domain screening

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.0K
Genome-wide Protein-protein Interaction Screening by Protein-fragment Complementation Assay PCA in Living Cells
08:38

Genome-wide Protein-protein Interaction Screening by Protein-fragment Complementation Assay PCA in Living Cells

Published on: March 3, 2015

17.8K

Related Experiment Videos

Last Updated: May 5, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

300
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.0K
Genome-wide Protein-protein Interaction Screening by Protein-fragment Complementation Assay PCA in Living Cells
08:38

Genome-wide Protein-protein Interaction Screening by Protein-fragment Complementation Assay PCA in Living Cells

Published on: March 3, 2015

17.8K

Area of Science:

  • Medicinal Chemistry
  • Cheminformatics
  • Computational Drug Discovery

Background:

  • Poly(ADP-ribose) polymerase 1 (PARP1) is a key therapeutic target in DNA repair-deficient cancers.
  • Challenges in PARP1 inhibitor discovery include scaffold convergence, tolerability issues, and acquired resistance.
  • Development of novel, effective PARP1 inhibitors is crucial for advancing cancer treatment.

Purpose of the Study:

  • To create an interpretable and reliable cheminformatics workflow for prioritizing PARP1 inhibitors.
  • To integrate quantitative structure-activity relationship (QSAR) modeling with structure-based drug design.
  • To facilitate the identification of novel PARP1 inhibitors with improved potency and drug-like properties.

Main Methods:

  • A curated dataset of 3339 PARP1 inhibitors from ChEMBL was utilized.
  • Machine learning models, including a stacked ensemble, were trained using RDKit descriptors and Avalon fingerprints.
  • Feature selection, model interpretation (SHAP, permutation importance), external validation via PubChem similarity expansion, and molecular docking (AutoDock Vina, SwissDock) were employed.

Main Results:

  • The stacked ensemble model demonstrated strong predictive performance (test R² = 0.723, RMSE = 0.610 pIC₅₀ units).
  • External validation confirmed the model's utility, with a positive association between predicted and experimental activities (R² = 0.124, Pearson r = 0.479).
  • Three promising drug candidates (CID 168873053, CID 175154210, CID 172894737) were identified through complementary docking analysis.

Conclusions:

  • The developed workflow offers a transparent and practical framework for prioritizing PARP1 inhibitors.
  • The integrated approach of QSAR, explainability, external corroboration, and docking effectively supports the generation of lead compounds.
  • This strategy aids in accelerating the discovery of novel PARP1 inhibitors for experimental validation and potential therapeutic applications.